Cobra Biologics
The international CDMO for biologics and pharmaceuticals has appointed Dr. Darrell Sleep as the director of innovation.
According to Cobra, the decision is part of ongoing strategic expansions activities underway at the company’s Keele site. This includes increasing capacity and capability for the clinical and commercial in-market supply of viral vector and DNA products to advanced therapy medicinal product (ATMP) developers.
In his new role, Darrell will lead the site’s newly-formed innovation team. He also will work closely with the group’s chief scientific officer (CSO) Professor Daniel Smith.
Sleep told us, “In the first instance, the integration of the internal R&D and the process & analytical development teams will facilitate improved knowledge and information flow between the two departments.
“I look forward to the combined team delivering process development improvements through the adoption of optimised workflows and the introduction of innovative bioprocess solutions for biotech companies developing ATMPs.”